Interactive demonstration · synthetic data

Laboratory result.

A received blood panel for a patient on methotrexate. It evidences an open monitoring item and carries a laboratory flag for clinician review.

Each scenario has its own address, and the address keeps your place, so you can share it or come back to it. Reset at any time.

Take the 90-second tourA scripted walkthrough of the clinic-letter scenario, from receipt to evidence. Pause, step or skip at any point; synthetic data throughout.
Synthetic

Illustrative product demonstration using synthetic clinical information. It does not establish the clinical accuracy, safety or readiness of the product. Nothing is saved to any clinical record, and nothing you do here is sent anywhere.

ReedleySynthetic
Patricia LOWE synthetic patient58 y · DOB 22 Nov 1967 · NHS 999 000 0387 · Synthetic Practice
Identity matchedClassified Pathology result · Haematology and biochemistry

Step 1 of 3 Open an item to see the passage it came from, then accept, edit or reject it. 0 of 2 decided.

Source document

Numbers mark the passages each item cites.
Northfield Pathology (fictional)Haematology and clinical biochemistryPathology reportCollected 13 Oct 2026 08:40 · Reported 14 Oct 2026 09:05 · Received 14 Oct 2026 09:12Patient: Patricia LOWE · DOB 22 Nov 1967 · NHS 999 000 0387

Request

Requested by Synthetic Practice. Clinical details: methotrexate monitoring.13

Full blood count1

TestResultReference rangeFlag
Haemoglobin128 g/L115–165
White cell count6.1 ×10⁹/L4.0–11.0
Neutrophils3.8 ×10⁹/L2.0–7.5
Platelets251 ×10⁹/L150–400

Liver function1

TestResultReference rangeFlag
ALT262 U/L0–40H
ALP84 U/L30–130
Bilirubin9 µmol/L0–21
Albumin41 g/L35–50

Urea and electrolytes1

TestResultReference rangeFlag
Sodium139 mmol/L133–146
Potassium4.4 mmol/L3.5–5.3
Creatinine71 µmol/L45–84
eGFR81 mL/min/1.73m²

Laboratory comment

ALT above reference range.2 Please interpret in the clinical context.

Synthetic document created for demonstration. Not a real patient.

Open work and proposed work 3

Each item shows the findings and the exact passages it comes from. Open one to decide on it.

  1. Item 1 of 3: Monitoring dueMethotrexate monitoring bloods: FBC, LFT, U&EVerified

    From the document

    Open work this document affects

    Owner
    Admin team
    Due
    13 Oct 2026
    Status
    Verified

    Evidence in this document Pathology: FBC, LFT and U&E received 14 Oct 2026 09:12 for this patient (this report). (Simulated) The monitoring bloods were taken and reported.

    Verified when: All three panels received for this patient within the window. Source: Pathology, by design; simulated here.

    Limit A received result is not a reviewed result. The laboratory flag goes to a clinician as its own item, and this item is designed to close only after that review is recorded (the development build closes it on receipt).

    Closes after: item 2, Clinician review of the received result: laboratory flag on ALT.

    Already in the work queue
  2. Item 2 of 3: Result reviewClinician review of the received result: laboratory flag on ALTReview today

    From the document

    • Laboratory flagLab flag present

      ALT 62 U/L — flagged H by the laboratory

      Shown exactly as the laboratory reported it. Reedley does not interpret results.

      Record Previous ALT: 38 U/L (14 Apr 2026), 34 U/L (21 Jul 2026).

      Why Reedley says this The laboratory applied a flag to this value; the practice rule routes flagged results on a monitored medicine to a clinician.

    Proposed work

    Practice rule (draft): a laboratory flag on a medicine with shared-care monitoring goes to a clinician.

    Owner
    Clinical pharmacist
    Due
    Today
    Who decides
    Prescriber review required

    Verified when: A review entry recorded by a named clinician, with the date. Source: Clinical record, by design; simulated here.

    Limit It shows that a review was recorded, not what it concluded. Reedley does not interpret results.

    Reedley does not say what the result means or what to do. A clinician decides.

    Reedley proposes; a named person decides. Nothing happens until you do.

  3. Item 3 of 3: MonitoringNext methotrexate monitoring bloods (interval set by the clinician reviewing the ALT)Proposal

    From the document

    Proposed work

    The shared-care schedule in this synthetic practice repeats every 12 weeks, but the next interval waits for the clinician reviewing the flagged ALT. The 12-week interval is a draft, unsigned rule.

    Owner
    Admin team
    Due
    Interval set by the clinician reviewing the ALT
    Who decides
    Subject to clinician review
    After
    Item 2: Clinician review of the received result: laboratory flag on ALT

    Verified when: The next FBC, LFT and U&E received for this patient within the interval the reviewing clinician sets. Source: Pathology, by design; simulated here.

    Monitoring intervals are designed to come from a rule a named clinician owns. Today the rule is an unsigned draft with no named owner.

    Reedley proposes; a named person decides. Nothing happens until you do.

For information · no action proposed

What the record shows (synthetic)

Current medicines

  • Methotrexate 2.5 mg tablets 15 mg once weekly (Friday) Shared care
  • Folic acid 5 mg tablets Once weekly (not Friday) Repeat

Problems

Rheumatoid arthritis

Context

Shared-care agreement
Rheumatology, synthetic protocol v3 (illustrative)
Monitoring rule
FBC, LFT, U&E every 12 weeks (draft, unsigned)
Previous ALT
38 U/L (14 Apr) · 34 U/L (21 Jul)
Latest

#5 · 14 Oct 09:20 · Reedley Verified from source · Methotrexate monitoring bloods: FBC, LFT, U&E

Synthetic data · Illustrative concept · Not clinical rules · Not a live system · Source checks are simulated

 

What the demonstration does not show

Real accuracy. These outputs were written in advance. They do not show how often the product extracts information correctly from real documents; that has not yet been measured.

Real integration. There is no connection to EMIS Web, SystmOne or any laboratory, and nothing is written to any record. “Source checks” are simulated to show how verification is meant to work once approved access exists.

Clinical rules. Intervals, routing rules and wording are illustrative. In the product, clinical rules are designed to be owned by named clinicians and versioned; today they are unsigned drafts with no named owner.

Next steps

See it on your own workflows.

In a pilot, your team would test Reedley on synthetic patients built around your real workflows before anything else happens.

  1. See it work

    A scripted walkthrough of a synthetic clinic letter, from receipt to evidence. Pause or step through it at any point.

    Take the 90-second tour
  2. Share it

    Ten short sections for partners, PCN leads and digital staff, written to be forwarded without a conversation first.

    Read the evaluation pack
  3. Talk to us

    Registering interest takes about a minute. A conversation is with Salim Miah, founder (MPharm, independent prescriber).

Questions buyers ask

What will it cost?

Pricing has not been set. Pilot participation would be agreed individually; we will not ask a practice to pay for something that is not ready.

Who is building Reedley?

Reedley is at an early stage and is currently founder-led. Its founder, Salim Miah MPharm, is a UK-qualified pharmacist and independent prescriber who has worked across community pharmacy, hospital and general practice.

As Reedley grows, clinical safety, engineering and information governance roles will be filled by suitably qualified people, and we will name them here.

How much of our team’s time does a pilot take?

Stage 1 is about an hour; registering interest takes about a minute and applying about five minutes.

Stages 2–4 are agreed with you in the conversation; we will not guess.

Does it work with EMIS Web or SystmOne?

Not today. Reedley is designed around EMIS Web workflows, but no integration exists, none is claimed, and no supplier has approved or partnered with Reedley.

We intend to pursue the published integration routes, such as IM1 pairing, and will report each step on the integration page.

The same applies as for EMIS Web: designed for SystmOne workflows, with no integration existing or claimed.

All questions and answers